

ASX RELEASE**Scheme Materials**

Wellington, NZ, 20 March 2024: [Volpara Health Technologies Limited](#) (“Volpara”; ASX:VHT) released an electronic version of the following documents (the “Scheme Materials”) to the market on 13 March 2024:

- Scheme Booklet including an Independent Adviser’s Report and Notice of Meeting;
- Scheme Meeting Proxy Form; and
- Online Meeting Guide.

Volpara advises that physical copies of the Scheme Materials have now been posted to shareholders, holders of out of the money options and other parties as required by the initial orders, ahead of the Scheme Meeting at 11:00am (Sydney time) on Friday, 12 April 2024, to be held both in person at MinterEllison, Level 40, Governor Macquarie Tower, 1 Farrer Place, Sydney, Australia and online at <https://web.lumiagm.com/331-237-318>.

The Scheme Materials are also available at <https://www.volparahealth.com/investors/market-announcements/>.

Authorisation & Additional Information

This announcement was authorised by the CEO & MD of Volpara Health Technologies Limited.

ENDS

For further information please contact:

Corporate enquiries

Teri Thomas, CEO & MD

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 4 499 6029

Investor relations

Shareholder Information Line

Toll: 1300 513 794

AU Toll-free: +61 2 9066 4082

NZ Toll-free: +64 9 889 6570

Media enquiries

Clive Mathieson

Cato & Clive

clive@catoandclive.com

t: 61 411 888 425

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. Volpara helps leading healthcare providers positively impact their patients and families around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain mammogram quality, provide objective mammogram density, and speed up and smooth the arduous reporting necessary for mammography accreditation.

Volpara's focus on customer value means that its AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, Volpara's software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. With a strong sales base in the United States and Australia, Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit www.volparahealth.com